A Randomized, Participant- and Investigator-blinded, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral TMP-301 Given Concurrently With Cocaine
Latest Information Update: 26 May 2025
At a glance
- Drugs HTL 0014242 (Primary)
- Indications Cocaine-related disorders
- Focus Adverse reactions
- Sponsors Tempero Bio
Most Recent Events
- 18 May 2025 Status changed from recruiting to completed.
- 24 Mar 2025 According to a Tempero Bio media release, the company announced the closing of a $70 million Series B financing The proceeds will be used to advance TMP-301 through two Phase 2 clinical trials for alcohol use disorder and cocaine use disorder, as well as Phase 3-enabling activities and preclinical studies for additional indications and formulations.
- 20 Jan 2025 Status changed from not yet recruiting to recruiting.